SCHEMBL438847

SCHEMBL438847

CC(C)C1=C[N]C(=O)NC1=O

nearest known ligand 0.30

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
EEF2K O00418 1/20 0.30
PLK1 P53350 1/20 0.30
PLK2 Q9NYY3 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL143917 0.70
SCHEMBL440393 0.65
SCHEMBL3148368 0.65
SCHEMBL3148463 0.65
SCHEMBL545786 0.65 HKDC1 (0.33)
SCHEMBL3138242 0.65
SCHEMBL3152083 0.65
SCHEMBL442765 0.65 PIM1 (0.30)
SCHEMBL8554982 0.62
SCHEMBL17471236 0.62 EEF2K (0.35) EEF2KPLK1PLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230143643-A1 LOW DK COPPER CLAD LAMINATE COMPOSITIONS DESIGNER MOLECULES INC (US) 2023-05-11 US disclosed
US-20230095931-A1 UV-CURABLE RESIN COMPOSITIONS SUITABLE FOR REDISTRIBUTION LAYERS DESIGNER MOLECULES INC (US) 2023-03-30 US disclosed
US-20220213267-A1 EXTREME HIGH TEMPERATURE STABLE ADHESIVES AND COATINGS DESIGNER MOLECULES, INC 2022-07-07 US disclosed
US-20220204696-A1 PHENOLIC FUNCTIONALIZED POLYIMIDES AND COMPOSITIONS THEREOF DESIGNER MOLECULES, INC 2022-06-30 US disclosed
US-20220204766-A1 HIGH MOLECULAR WEIGHT FLEXIBLE CURABLE POLYIMIDES DESIGNER MOLECULES, INC 2022-06-30 US disclosed
US-20210301133-A1 CURABLE POLYIMIDES DESIGNER MOLECULES INC (US) 2021-09-30 US disclosed
WO-2021113415-A1 LOW DK COPPER CLAD LAMINATE COMPOSITIONS DESIGNER MOLECULES, INC (US) 2021-06-10 WO disclosed
CN-108291122-B Anionically curable compositions 设计分子有限公司 2021-01-05 CN disclosed
WO-2020219852-A1 PHENOLIC FUNCTIONALIZED POLYIMIDES AND COMPOSITIONS THEREOF DESIGNER MOLECULES, INC. (US) 2020-10-29 WO disclosed
WO-2020215025-A1 EXTREME HIGH TEMPERATURE STABLE ADHESIVES AND COATINGS DESIGNER MOLECULES, INC (US) 2020-10-22 WO disclosed
EP-1594835-A4 METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES AUSPEX PHARMACEUTICALS INC (US) 2007-05-02 EP disclosed
WO-2007041630-A1 DEUTERATED INHIBITORS OF GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES AUSPEX PHARMACEUTICALS, INC. (US) 2007-04-12 WO disclosed
US-20070082929-A1 Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties AUSPEX PHARMACEUTICALS, INC. 2007-04-12 US disclosed
US-20060173199-A1 Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses HONG BORCHERNG 2006-08-03 US disclosed
WO-2006041921-A2 PREPARATION AND USES OF RHODANINE DERIVATIVES AUSPEX PHARMACEUTICALS, INC. (US) 2006-04-20 WO disclosed
EP-1594835-A2 METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES Auspex Pharmaceuticals, Inc. (US) 2005-11-16 EP disclosed
WO-2005049582-A1 METHOD OF PREPARATION OF NOVEL NUCLEOSIDE ANALOGS AND USES AUSPEX PHARMACEUTICALS, INC. (US) 2005-06-02 WO disclosed
WO-2004064745-A2 METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES AUSPEX PHARMACEUTICALS, INC. (US) 2004-08-05 WO disclosed
US-5631259-A PURINE BASE DERIVATIVES FOR NUCLEOSIDES HOECHST AKTIENGESELLSCHAFT (DE) 1997-05-20 US disclosed
EP-0521463-A2 Substituted cyclic cycloalkyltriols, process, intermediates for their preparation and their use as antiviral and antiparasitic agents HOECHST AKTIENGESELLSCHAFT (DE) 1993-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070082929-A1 Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties ATP4A, ATP6V1G1, ATP6V1E1 EEF2K 543/4885PLK1 2080/4885PLK2 4144/4885
US-20060173199-A1 Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses LSS, DHPS, CYP51A1 EEF2K 3449/4885PLK1 2209/4885PLK2 350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.